alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 176–200 of 222 studies with an author at University of California, Irvine (US) (page 8 of 9) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 222 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 16,452 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Alzheimer-related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD?

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2020-11-07

Our findings suggest that quantification of WM changes in DS could provide a promising and clinically relevant biomarker for AD clinical onset and progression. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Research attitudes in families of individuals with Down syndrome: importance for clinical trials

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2022-11-23

This is one of the first formal studies to evaluate research attitudes among relatives of individuals with DS and shows the feasibility of using this approach to answer important questions that will guide trialists developing treatments for AD in DS. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuron 2022-04-25

People with Down syndrome (DS) have increased risk of Alzheimer disease (AD), presumably conferred through genetic predispositions arising from trisomy 21. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Digital Health Literacy and Self-Efficacy in Using Digital Health Resources Among Caregivers of Individuals with Alzheimer’s Disease and Related Dementias

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Sage Open Aging 2025-12-01

This study explored digital health literacy skills, self-efficacy in utilizing digital health resources, and self-efficacy in managing personal health among caregivers of individuals with Alzheimer's disease and related dementias (ADRD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

End-of Life Care Disparities Experienced by American Indian and Alaska Natives Peoples: An Analysis of Data from the 2019 Medicare Master Beneficiary Summary File

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Palliative Medicine 2025-05-27

AI/AN patients at the end-of-life were more likely to be hospitalized and less likely to use hospice compared with their NHW counterparts. 4 key findings →

Participants: 6,975 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Proceedings of the National Academy of Sciences of the United States of America 1991-11-01

The amyloid beta protein and the amyloid beta-protein precursor (APP) are major constituents of senile plaques and cerebrovascular deposits in patients with Alzheimer disease and Down syndrome. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer's research & therapy 2019-12-17

Alzheimer disease (AD) is characterized by the accumulation of beta-amyloid (Aβ) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline. 4 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Asian Americans & Racism: Individual and Structural Experiences (ARISE) Pilot Study: Cultural and Linguistic Considerations in Studying Chinese, Vietnamese, and Korean American Older Adults

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer s & Dementia 2025-12-01

Recruitment strategies are tailored in collaboration with community organizations to align with each language group's preferences, including adjusting the blood draw and interview sequence and hosting group blood draws where participants completed the procedure together, fostering a sense of community and reducing anxiety. 5 key findings →

Participants: 252 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Endothelial progenitor cells and cerebral small vessel disease in APOE4 carriers

✓ Peer-reviewed alzhub usefulness score 39 out of 100. Cerebral Circulation - Cognition and Behavior 2025-01-01

• APOE4 carriers exhibit cerebrovascular dysfunction. • Endothelial progenitor cells (EPC) represent cell populations involved in facilitating vascular repair. • In APOE4 carriers, EPC colony count is associated with cerebral small vessel disease. • EPC colony count may indicate activation of mechanisms which protect cerebrovascular function in APOE4 carriers prior to the development of cognitive decline. 4 key findings →

Participants: 109 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Regional binding of tau and amyloid PET tracers in Down syndrome autopsy brain tissue

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Molecular neurodegeneration 2020-11-23

This study provides new insights into the regional binding distribution of a first-generation and a second-generation Tau tracer in limbic and neocortical regions in adults with DS, as well as regional differences in Tau binding in adult with DS vs. those with AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Synaptic actin stabilization protein loss in Down syndrome and Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Brain pathology (Zurich, Switzerland) 2019-09-08

Reduced spine densities and age-dependent accumulation of amyloid β and tau pathology are shared features of Down syndrome (DS) and Alzheimer's disease (AD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Breast cancer screening among Medicare Advantage enrollees with dementia

✓ Peer-reviewed alzhub usefulness score 38 out of 100. BMC Health Services Research 2024-03-05

Mammogram utilization was 16% higher (Prevalence Ratio [PR] 1.16; 95% CI: 1.05, 1.29) among Medicare Advantage enrollees with dementia, compared to their counterparts in fee-for-service Medicare. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Telemedicine, dementia and Down syndrome: implications for Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2006-07-01

This study supports the need for formal reliability and validity studies of TM preparatory to the consideration of this modality for use in clinical trials for AD. 1 key finding →

Participants: 90 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular syndromology 2018-10-30

In the last decade, a number of important research advances in different fields have allowed Down syndrome (DS) research to flourish, creating a time of both unparalleled opportunity and considerable challenge. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events